Pancreatic cancer clues: new protein study could refine prognosis
NCT ID NCT06705335
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study is analyzing tumor and blood samples from 50 people with pancreatic cancer to measure levels of certain proteins called convertases. Researchers want to see if these protein levels are linked to immune cells in the tumor, which could help predict how the disease will progress. The study does not test any new treatment, but aims to improve understanding of the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a new way to predict how pancreatic cancer will progress, helping doctors tailor treatments.
- What could go wrong
- This is a small, early observational study, not a treatment trial. It may not find a clear link, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Bergonié, Comprehensive Cancer Center
RECRUITINGBordeaux, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- Can a new ultrasound technique spot hidden pancreatic cancers earlier?
- A sound wave that could expose hidden pancreatic cancer?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- A simple breath test might spot multiple cancers before symptoms appear
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?